Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772].
Ann Oncol
; 33(3): 355, 2022 Mar.
Article
de En
| MEDLINE
| ID: mdl-35012798
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Type d'étude:
Prognostic_studies
/
Risk_factors_studies
Langue:
En
Journal:
Ann Oncol
Sujet du journal:
NEOPLASIAS
Année:
2022
Type de document:
Article
Pays d'affiliation:
Allemagne
Pays de publication:
Royaume-Uni